Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ERN1 | O75460 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465591 | 0.92 | ERN1 (0.42) | ALDH1A1LMNAMAPTPOLBERN1 | |
| SCHEMBL6237455 | 0.91 | MAPT (0.42) | ALDH1A1LMNAMAPTPOLBERN1 | |
| SCHEMBL6465588 | 0.89 | ERN1 (0.43) | ALDH1A1LMNAMAPTPOLBERN1 | |
| SCHEMBL6233340 | 0.89 | ERN1 (0.43) | ALDH1A1LMNAMAPTPOLBERN1 | |
| SCHEMBL7643417 | 0.88 | ERN1 (0.38) | ALDH1A1LMNAMAPTPOLBERN1 | |
| SCHEMBL2329831 | 0.82 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPTERN1SMN1; SMN2 | |
| SCHEMBL5671783 | 0.80 | MGLL (0.37) | ALDH1A1 | |
| SCHEMBL14634320 | 0.79 | RORC (0.40) | ALDH1A1MAPTSMN1; SMN2GAAMEN1 | |
| SCHEMBL6459702 | 0.79 | PTGDR2 (0.41) | ALDH1A1LMNAMAPTPOLBERN1 | |
| SCHEMBL2562538 | 0.78 | ERN1 (0.46) | ALDH1A1MAPTPOLBERN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855842-B1 | Intermediates for making a bezofuran or benzothiophene derivative nitrated in position 5 and uses thereof | RHODIA CHIMIE (FR) | 2005-02-15 | — | — | US | claimed |
| US-7312345-B2 | Process for the preparation of dronedarone | ISP INVESTMENTS INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20050113596-A1 | Nitrating a 2-(2-formylphenoxy) or 2-(2-formylphenylsulfido) alkyl ester or alkoic acid in the presence of sulfuric acid | SHASUN PHARMA SOLUTIONS, INC. | 2005-05-26 | — | — | US | disclosed |
| US-6855842-B1 | Intermediates for making a bezofuran or benzothiophene derivative nitrated in position 5 and uses thereof | RHODIA CHIMIE (FR) | 2005-02-15 | — | — | US | disclosed |
| US-6555697-B1 | Cyclizing a 1-(2-carboxyethyloxy or thio-),2-formylbenzene in the presence of an efficient amount of a carbonate base in a medium comprising a carboxylic acid anhydride; intermediate for 2-n-butyl-5-nitrobenzofuran | RHODIA CHIMIE (FR) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113596-A1 | Nitrating a 2-(2-formylphenoxy) or 2-(2-formylphenylsulfido) alkyl ester or alkoic acid in the presence of sulfuric acid | SULT1A1, SULT1E1, FPR1 | ALDH1A1 111/4885LMNA 3643/4885MAPT 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.